NYSE:RMED

Stock Analysis Report

Executive Summary

Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases.

Snowflake

Fundamentals

Excellent balance sheet with limited growth.

Risks

  • Ra Medical Systems has significant price volatility in the past 3 months.
  • Ra Medical Systems is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Ra Medical Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-13.9%

RMED

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

RMED

9.9%

US Medical Equipment

0.7%

US Market

No trading data on RMED.

No trading data on RMED.


Share holder returns

RMEDIndustryMarket
7 Day-13.9%1.1%-0.6%
30 Day-20.3%1.3%2.9%
90 Day-55.8%3.0%1.3%
1 Yearn/a10.8%9.9%2.9%0.7%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Ra Medical Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

4 months ago | Simply Wall St

What Should You Know About Ra Medical Systems, Inc.'s (NYSE:RMED) Growth?

Valuation

Is Ra Medical Systems undervalued based on future cash flows and its price relative to the stock market?

0.32x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Ra Medical Systems to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Ra Medical Systems to establish if it is available at substantial discount.


Price Based on Earnings

Ra Medical Systems is loss making, we can't compare its value to the US Medical Equipment industry average.

Ra Medical Systems is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Ra Medical Systems, we can't assess if its growth is good value.


Price Based on Value of Assets

Ra Medical Systems is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Ra Medical Systems expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

0.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Ra Medical Systems's revenue is expected to grow significantly at over 20% yearly.

Ra Medical Systems is not considered high growth as it is expected to be loss making for the next 1-3 years.

Ra Medical Systems's revenue growth is expected to exceed the United States of America market average.

Unable to compare Ra Medical Systems's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Ra Medical Systems's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Ra Medical Systems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Ra Medical Systems performed over the past 5 years?

-127.8%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ra Medical Systems does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Ra Medical Systems's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Ra Medical Systems's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Ra Medical Systems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Ra Medical Systems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Ra Medical Systems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Ra Medical Systems's financial position?


Financial Position Analysis

Ra Medical Systems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Ra Medical Systems's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Ra Medical Systems's level of debt (1.6%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Ra Medical Systems's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 62.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Ra Medical Systems has sufficient cash runway for 2.1 years based on current free cash flow.

Ra Medical Systems has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 84.2% each year.


Next Steps

Dividend

What is Ra Medical Systems's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Ra Medical Systems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Ra Medical Systems's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Ra Medical Systems has not reported any payouts.

Unable to verify if Ra Medical Systems's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Ra Medical Systems has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Ra Medical Systems's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Andrew Jackson (50yo)

0.08yrs

Tenure

0

Mr. Andrew C. Jackson has been the Chief Financial Officer of Ra Medical Systems, Inc. since April 2018 and served as its Secretary since July 2018. Mr. Jackson has been an Interim Chief Executive Officer  ...


Management Age and Tenure

0.8yrs

Average Tenure

52.5yo

Average Age

The average tenure for the Ra Medical Systems management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.2yrs

Average Tenure

61yo

Average Age

The average tenure for the Ra Medical Systems board of directors is less than 3 years, this suggests a new board.


Insider Trading

Ra Medical Systems individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$34,97223 Jul 19
Jeffrey Kraws
EntityIndividual
Role
President
President
Shares11,930
Max PriceUS$2.93
SellUS$41,92522 Jul 19
Dean Irwin
EntityIndividual
Role
Member of the Board of Directors
Director
Shares14,302
Max PriceUS$2.93
SellUS$25,16322 Jul 19
Melissa Burstein
EntityIndividual
Shares8,584
Max PriceUS$2.93
SellUS$55,43817 Jun 19
Jeffrey Kraws
EntityIndividual
Role
President
President
Shares18,021
Max PriceUS$3.08
SellUS$15,79417 Jun 19
Andrew Jackson
EntityIndividual
Role
Chief Executive Officer
Interim CEO & CFO
Shares5,134
Max PriceUS$3.08
SellUS$52,47214 May 19
Dean Irwin
EntityIndividual
Role
Member of the Board of Directors
Director
Shares13,736
Max PriceUS$3.82
SellUS$31,50014 May 19
Melissa Burstein
EntityIndividual
Shares8,246
Max PriceUS$3.82
SellUS$45,90015 Apr 19
Dean Irwin
EntityIndividual
Role
Member of the Board of Directors
Director
Shares13,152
Max PriceUS$3.49
SellUS$27,13815 Apr 19
Melissa Burstein
EntityIndividual
Shares7,776
Max PriceUS$3.49

Ownership Breakdown


Management Team

  • Jeff Kraws (55yo)

    President

    • Tenure: 0.8yrs
    • Compensation: US$4.28m
  • Tom Fogarty (60yo)

    Chief Commercial Officer

    • Tenure: 0.8yrs
  • Andrew Jackson (50yo)

    Interim CEO & CFO

    • Tenure: 0.08yrs
  • Dan Horwood (45yo)

    General Counsel & Secretary

    • Tenure: 0.9yrs

Board Members

  • Marty Colombatto (60yo)

    Chairman & Lead Independent Director

    • Tenure: 0.7yrs
    • Compensation: US$1.56m
  • Dean Irwin (56yo)

    Director

    • Tenure: 0yrs
    • Compensation: US$10.87m
  • Maurice Buchbinder (66yo)

    Director

    • Tenure: 2.7yrs
    • Compensation: US$1.55m
  • Mark Saad (49yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$129.69k
  • Richard Mejia (70yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$131.95k
  • Bill Enquist (62yo)

    Director

    • Tenure: 1.2yrs
    • Compensation: US$127.91k

Company Information

Ra Medical Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ra Medical Systems, Inc.
  • Ticker: RMED
  • Exchange: NYSE
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$19.264m
  • Shares outstanding: 12.93m
  • Website: https://www.ramed.com

Number of Employees


Location

  • Ra Medical Systems, Inc.
  • 2070 Las Palmas Drive
  • Carlsbad
  • California
  • 92011
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RMEDNYSE (New York Stock Exchange)YesCommon StockUSUSDSep 2018
4RMDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2018

Biography

Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. The company offers  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/22 00:54
End of Day Share Price2019/09/20 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.